Twenty-one-gene recurrence score assay inBRCA-associated versus sporadic breast cancers: Differences based on germline mutation status

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

(2014) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

(2013) Steven A. Narod et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

(2011) Mieke Kriege et al.   CANCER

Response to Neoadjuvant Systemic Therapy for Breast Cancer inBRCAMutation Carriers and Noncarriers: A Single-Institution Experience

(2011) Banu Arun et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study

(2011) Pamela J. Goodwin et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Approaches for Women Predisposed to Breast Cancer

(2010) Katherine L. Nathanson et al.   Annual Review of Medicine

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer inBRCA1andBRCA2Mutation Carriers

(2009) Mieke Kriege et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY